Growth hormone axis
IGF-1 LR3
Also called Long R3 IGF-1
per administration
Only animal or lab studies exist — no human study has set an amount.
Quick start
IGF-1 LR3 at a glance — the figures, plus how it's commonly run. Reference only, not medical advice.
- Typical dose
- 20–50 mcg per administration
- How often
- Every day
- Where
- Commonly subcutaneous Sites and rotation
- Time to steady level
- ~4.2 days — about five half-lives
- Storage
- Dry vial kept cold and dark; a mixed vial in the fridge at 2–8 °C. Details
A research and community reference, not medical advice. Figures are descriptive, vary between sources, and are not a recommendation for use.
Work out your draw
These numbers are a starting point — change any of them.
Vial label
Copy this into your label printer.
Published research contexts for IGF-1 LR3 describe 20–50 mcg per administration. Descriptive only, not a recommendation.
Community figures put it far longer than native IGF-1 because it binds IGF-binding proteins weakly; human pharmacokinetics are not established.
An IGF-1 analog sold mainly as a cell-culture reagent; no human dose-ranging study fixes an injected amount or schedule, so no schedule table is shown.
Modelled level — every day
1× is the peak after a single dose.
- Steady-state peak
- 1.77× single dose
- Time to steady state
- 4.2days
- Administrations
- 7/ week
Read off the modelled curve, not an even-interval formula
About five half-lives
Where these numbers come from
- Long R3 IGF-1 laboratory-reagent literatureAn IGF-1 analog with weak IGF-binding-protein affinity, sold mainly as a cell-culture reagent; human injected amounts are community-derived.